The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
Primary Objectives: Aim 1. Determine the metabolite and lipid profiles of MPNST, neurofibroma, and nerve tissues Aim 2. Validate the handheld mass spectrometry device (MSPen-Orbitrap system) for MPNST and neurofibroma diagnosis and for intraoperative surgical margin evaluation
Study Type
OBSERVATIONAL
Enrollment
60
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
RECRUITINGSafety and Adverse Events (AEs)
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time frame: Through study completion; an average of 1 year.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.